 |
인쇄하기
취소
|
Bukwang teams up with LSK Biopartners over investigational anticanger drug
Bukwang Pharm has acquired the exclusive license from the US based LSK Biopartners to develop, manufacture and market the compound YN968D1 in Korea, it was announced on January 8.
This compound s a potent, orally administered small-molecule angiogenesis inhibitor with the potential to fight solid tumor cancers.
YN968D1 is a highly selective VEGF receptor 2 (VEGFR-2) inhibitor being develo...
This compound s a potent, orally administered small-molecule angiogenesis inhibitor with the potential to fight solid tumor cancers.
YN968D1 is a highly selective VEGF receptor 2 (VEGFR-2) inhibitor being develo...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.